Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

Link
https://www.globenewswire.com/news-release/2025/02/12/3025225/0/en/Invitation-t…
Created date
Nasdaq ID
3025225
Last updated: 2025.02.12

Senior IT Architect (IAM and Cloud)

EasyCruit ID
3460585
Department ID
160433
Location
Kraków, Poland
Vacancy URL
https://alkabello.easycruit.com/vacancy/3460585/160433
Expire Date
Last updated: 2025.05.29

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

Link
https://www.globenewswire.com/news-release/2025/01/30/3017756/0/en/ALK-s-house-…
Created date
Nasdaq ID
3017756
Last updated: 2025.01.30

Fullstack Developer

EasyCruit ID
3458671
Department ID
220831
Location
Kraków
Vacancy URL
https://alkabello.easycruit.com/vacancy/3458671/220831
Expire Date
Last updated: 2025.05.29

ALK – Financial calendar for the 2025 financial year

Link
https://www.globenewswire.com/news-release/2024/12/20/3000728/0/en/ALK-Financia…
Created date
Nasdaq ID
3000728
Last updated: 2024.12.20

Positive results advance peanut tablet to phase II development

Link
https://www.globenewswire.com/news-release/2024/12/18/2998913/0/en/Positive-res…
Created date
Nasdaq ID
2998913
Last updated: 2024.12.18

ALK Christmas Party

GO BACK TO NEWS
Last updated: 2024.12.17

ACARIZAX® approved in Europe for treatment of young children

Link
https://www.globenewswire.com/news-release/2024/12/12/2996326/0/en/ACARIZAX-app…
Created date
Nasdaq ID
2996326
Last updated: 2024.12.12

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

Link
https://www.globenewswire.com/news-release/2024/11/27/2988155/0/en/ALK-s-pivota…
Created date
Nasdaq ID
2988155
Last updated: 2024.11.27

Nine-month interim report (Q3) 2024 (unaudited)

Link
https://www.globenewswire.com/news-release/2024/11/14/2980828/0/en/Nine-month-i…
Created date
Nasdaq ID
2980828
Last updated: 2024.11.14
Subscribe to